{"id":9601,"date":"2026-06-10T17:21:09","date_gmt":"2026-06-10T09:21:09","guid":{"rendered":"https:\/\/chimebiologics.com\/?p=9601"},"modified":"2026-06-10T17:24:16","modified_gmt":"2026-06-10T09:24:16","slug":"cytiva-event-2026","status":"publish","type":"post","link":"https:\/\/chimebiologics.com\/ja\/cytiva-event-2026\/","title":{"rendered":"(English) Chime Biologics Unveils Next-Generation Global Biomanufacturing Vision at Global Biopharmaceutical Manufacturing Innovation Summit"},"content":{"rendered":"

\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000English<\/a>\u3068 \u4e2d\u6587<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p>

<\/p>\n

Chime Biologics Unveils Next-Generation Global Biomanufacturing Vision at Global Biopharmaceutical Manufacturing Innovation Summit<\/strong><\/h1>\n

Wuhan, China | June 8, 2026<\/strong> \u2014 Chime Biologics, a global biologics CDMO dedicated to enabling partners\u2019 success, announced a series of major milestones that mark the company\u2019s evolution from an early pioneer in modular biologics manufacturing toward an AI-powered Megafactory vision designed for the future paradigm of global biologics manufacturing during the Global Biopharmaceutical Manufacturing Innovation Summit.<\/p>\n

Under the theme \u201cFrom Modular Innovation to Intelligent Megafactory,\u201d the summit highlighted five strategic initiatives shaping the next era of Chime Biologics\u2019 global manufacturing platform.<\/p>\n

\"\"<\/p>\n

KUBio 10th Anniversary: A Pioneer in Modular Biologics Manufacturing<\/h4>\n

In 2016, Chime Biologics installed the world\u2019s first KUBio modular biologics facility for commercial-scale biosimilar manufacturing, becoming one of the earliest global pioneers in both single-use manufacturing technologies and commercial biosimilar production.<\/p>\n

Over the past decade, the company has continued to expand its biologics manufacturing capabilities while contributing to the broader adoption of flexible manufacturing systems across the global biopharmaceutical industry.<\/p>\n

\"\"<\/p>\n

GMP-2 Officially Launches<\/h4>\n

Chime Biologics also officially launched its GMP-2 facility featuring 8 \u00d7 2000L single-use bioreactor capacity from Cytiva.<\/p>\n

Designed to support late-phase and commercial manufacturing, GMP-2 provides flexible and scalable manufacturing solutions for global biologics partners seeking accelerated commercialization and reliable global supply.<\/p>\n

\"\"<\/p>\n

AI-Powered Megafactory Vision Unveiled<\/strong><\/h4>\n

Looking toward 2036, Chime Biologics unveiled its vision for a next-generation AI-powered Megafactory featuring over 100 \u00d7 2000L bioreactor capacity.<\/p>\n

Planned to become the single largest commercial biologics manufacturing facility in China, the Megafactory will integrate intelligent manufacturing systems, AI-enabled CMC platforms, and highly efficient supply chain ecosystems (Chime Innovation Alliance) to deliver both quality and cost leadership for global biologics programs.<\/p>\n

\"\"<\/p>\n

Global Dual-Source Strategy Announced with Rezon Bio<\/strong><\/h4>\n

To further strengthen global manufacturing resilience, Chime Biologics officially announced its collaboration with Poland-based biologics CDMO Rezon Bio as part of its Global Dual-Source Strategy.<\/p>\n

The initiative is designed to combine China\u2019s manufacturing efficiency with resilient global supply capabilities, helping clients mitigate geopolitical risks, tariff uncertainties, and evolving regulatory requirements while ensuring long-term supply continuity.<\/p>\n

\"\"<\/p>\n

Strategic Collaboration Expanded with Sino Pharmengin<\/strong><\/h4>\n

Chime Biologics also announced the further expansion of its collaboration with Sino Pharmengin for the development of its future Megafactory project.<\/p>\n

As a leading engineering company under Sino Pharm, Sino Pharmengin has supported many of China\u2019s largest and most advanced biologics manufacturing facilities. Leveraging extensive expertise in large-scale biologics infrastructure and advanced equipment integration, Sino Pharmengin will serve as a key strategic partner in the development of Chime Biologics\u2019 next-generation intelligent manufacturing campus.<\/p>\n

\"\"<\/p>\n

\u201cOver the past decade, Chime Biologics has continuously evolved from modular innovation and single-use manufacturing pioneer toward a next-generation intelligent biomanufacturing platform,\u201d said Dr. Jimmy Wei, Board Director and CEO of Chime Biologics<\/strong>. \u201cWe believe the future of biologics manufacturing will require not only larger scale, but also smarter operations, more flexible commercialization capabilities, and more resilient global supply networks. Our GMP-2 launch, Megafactory vision, and Global Dual-Source Strategy together represent Chime Biologics\u2019 long-term commitment to helping global partners accelerate biologics commercialization with quality, efficiency, and reliability.\u201d<\/p>\n

As biologics innovation, AI technologies, and global manufacturing increasingly converge, Chime Biologics is positioning itself as a next-generation global biologics CDMO built for intelligent scale, flexible commercialization, and resilient worldwide supply.<\/p>\n

About Chime Biologics<\/b><\/strong><\/p>\n

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.<\/p>\n

For more information, please visit www.chimebiologics.com.<\/p>\n<\/div><\/section><\/div>\n